Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Journal for Immunotherapy of Cancer
Michael M BoyiadzisJames L Gulley

Abstract

The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval.

References

Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noralane M LindorStephen N Thibodeau
Jul 19, 2003·Pharmacological Reviews·Michael W N Deininger, Brian J Druker
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Sep 25, 2012·Current Colorectal Cancer Reports·Saima Sharif, Michael J O'Connell
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan P VenookMonica M Bertagnolli
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Jul 1, 2014·Genes·Rishabh SehgalDesmond C Winter
Jul 6, 2014·Clinical Chemistry·Stephen J SalipanteColin C Pritchard
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 3, 2015·Current Treatment Options in Oncology·Hisato KawakamiFrank A Sinicrope
Sep 1, 2015·International Journal of Oncology·Susan Richman
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter MohrMichael Weichenthal
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Mar 1, 2016·Advances in Immunology·Jeffrey P WardRobert D Schreiber
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 16, 2016·Current Opinion in Immunology·Ton N Schumacher, Nir Hacohen
Nov 1, 2016·Nature Medicine·Ronald J HauseStephen J Salipante
Feb 28, 2017·Journal for Immunotherapy of Cancer·Miles C Andrews, Jennifer A Wargo
Feb 28, 2017·Journal for Immunotherapy of Cancer·Patrick A OttJedd D Wolchok
May 13, 2017·Cell Reports·Angel Garcia-DiazAntoni Ribas
Jun 7, 2017·Nature Communications·Isidro Cortes-CirianoPeter J Park
Oct 27, 2017·Nature Communications·Moshe Sade-FeldmanNir Hacohen
Nov 7, 2017·Cell·Nicholas McGranahanUNKNOWN TRACERx Consortium

❮ Previous
Next ❯

Citations

Jul 19, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Vivek Subbiah, Kanishka Sircar
Jul 20, 2019·Journal of Oncology·Elaine GilmoreEileen E Parkes
May 28, 2019·Minerva medica·Giacomo CorradoGabriella Ferrandina
Jan 11, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kenneth OffitSemanti Mukherjee
Apr 3, 2020·Journal for Immunotherapy of Cancer·Luca MazzarellaGiuseppe Curigliano
May 21, 2020·Nature Reviews. Immunology·Alex D WaldmanMichael J Lenardo
Jun 2, 2020·American Society of Clinical Oncology Educational Book·Benedito A CarneiroRahul Aggarwal
Nov 26, 2019·Oncotarget·Connor WillisDavid D Stenehjem
Jun 23, 2020·Pharmacogenomics·Sylvie Brassart-PascoJean-Baptiste Oudart
May 15, 2020·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·A I DamanakisC J Bruns
Aug 29, 2020·Therapeutic Innovation & Regulatory Science·Alfredo Aram PuliniGregory Katz
Aug 23, 2018·Nature Reviews. Urology·Ravi A Madan, James L Gulley
May 10, 2019·Targeted Oncology·Kathy PanMihaela Cristea
Oct 9, 2019·Nature Reviews. Urology·Sheng-Yu KuHimisha Beltran
Oct 23, 2019·World Journal of Gastroenterology : WJG·Antonio PellinoMatteo Fassan
Apr 21, 2019·International Journal of Molecular Sciences·Kamila Wojas-KrawczykJanusz Milanowski
Dec 5, 2019·World Journal of Gastrointestinal Oncology·Shui-Ming WangYu Wang
Apr 18, 2020·Frontiers in Pharmacology·Cuicui XiaoQi Zhang
Mar 3, 2020·Frontiers in Immunology·Sara SaabHumam Kadara
Aug 26, 2020·Nature Communications·Akhilesh PandeySomasekar Seshagiri
Apr 13, 2019·Nature Reviews. Drug Discovery·Jessica VamathevanShanrong Zhao
Apr 9, 2020·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Lisa A FriedmanAnne M Mills
May 14, 2020·International Journal of Molecular Sciences·Michael Karl MelzerAlexander Kleger
Oct 28, 2019·Nature Reviews. Clinical Oncology·Benjamin G CarlisleJonathan Kimmelman
Feb 20, 2019·Clinical Drug Investigation·Long LongHonglei Chen
Nov 7, 2019·International Journal of Molecular Sciences·Fabio PagniNicola Fusco
Dec 26, 2018·Clinical and Experimental Immunology·A PawłowskaI Wertel
Apr 8, 2020·Frontiers in Cell and Developmental Biology·Aleksandra FilipovicJoseph Bolen
Jul 11, 2020·Pathology Oncology Research : POR·Cristina Díaz Del ArcoMª Jesús Fernández Aceñero
Nov 11, 2020·ELife·Jefte M DrijversMarcia C Haigis
Aug 16, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helen K AngellJérôme Galon
Jan 10, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SundarP Tan
Jan 27, 2021·Current Oncology Reports·Abigail L MendeJennifer L Clarke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.